151607-71-5

Basic information

• Product Name: (1-Trityl-1H-1,2,4-triazol-3-yl)methanol
• Synonyms: (1-Trityl-1H-1,2,4-triazol-3-yl)methanol;1H-1,2,4-Triazole-3-methanol, 1-(triphenylmethyl)-
• CAS NO: 151607-71-5
• Molecular Formula: C₂₂H₁₉N₃O
• Molecular Weight: 341.40576
• Mol File: 151607-71-5.mol

Chemical Properties

• Boiling Point: 560.5±60.0 °C(Predicted)
• Appearance: /
• Density: 1.15±0.1 g/cm3(Predicted)
• PKA: 13.16±0.10(Predicted)
• CAS DataBase Reference: (1-Trityl-1H-1,2,4-triazol-3-yl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (1-Trityl-1H-1,2,4-triazol-3-yl)methanol(151607-71-5)
• EPA Substance Registry System: (1-Trityl-1H-1,2,4-triazol-3-yl)methanol(151607-71-5)

Safety Data

• Hazardous Substances Data: 151607-71-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(1-Trityl-1H-1,2,4-triazol-3-yl)methanol serves as a valuable reagent in organic synthesis, where its trityl group provides the necessary stability and protection for nitrogen atoms during various chemical reactions.
Used in Pharmaceutical Research and Drug Development:
In the pharmaceutical industry, (1-Trityl-1H-1,2,4-triazol-3-yl)methanol is used as a building block for the synthesis of biologically active molecules, contributing to the development of new drugs and therapeutic agents. Its unique structure and properties make it a promising candidate for creating innovative and effective pharmaceutical compounds.

Upstream product

• 4928-88-5 methyl 1H-1,2,4-triazole-3-carboxylate 
• 76-83-5 trityl chloride 
• 151607-70-4 1-trityl-1H-[1,2,4]triazole-3-carboxylic acid methyl ester 

Downstream Products

• 163009-16-3 [1-(triphenylmethyl)-1H-1,2,4-triazol-3-yl]methyl methanesulfonate 
• 935760-24-0 3-[({[1-(triphenylmethyl)-1H-1,2,4-triazol-3-yl]methyl}oxy)methyl]benzonitrile 
• 637335-12-7 N-{4-[1-(2-fluoro-benzyl)-2,6-dioxo-3-(1-trityl-1H-[1,2,4]triazol-3-ylmethyl)-2,3,6,7-tetrahydro-1H-purin-8-ylmethyl]-phenyl}-acetamide 
• 163009-76-5 diphenylmethyl 7β-[(Z)-2-(2-aminothiazol-4-yl)-2-(trityloxyimino)acetamido]-3-[(1-trityl-1,2,4-triazol-3-yl)methylthio]-3-cephem-4-carboxylate 

Relevant articles and documents

SUBSTITUTED TETRAHYDROCYCLOPENTA[C]PYRROLES, SUBSTITUTED DIHYDROPYRROLIZINES, ANALOGUES THEREOF, AND METHODS USING SAME

The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) infection in a patient.

SUBSTITUTED NITROGEN CONTAINING COMPOUNDS

Disclosed are compounds of Formula (I): or a salt thereof, Formula (II) wherein R1 is: or; each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

PYRIDAZINE DERIVATIVES AS RORC MODULATORS

Compounds of formula (I): (I) or pharmaceutical salts thereof, wherein m, n,, p, q A, B, Ri, R2, R3, R4, R5, R6and R7are as defined herein. Also disclosed are methods of making the compounds and using the compounds as RORs modulators for treatment of inflammatory diseases such as arthritis.

HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF

The present invention provides a novel amide compound represented by the following formula, which has a matrix metalloproteinase inhibitory activity and is useful as a pharmaceutical agent. wherein each symbol is as defined in the specification.

Amide substituted xanthine derivatives

The present invention is a 1,3,8 substituted xanthine derivative of formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are as defined in the specification. Compounds of formula I and pharmaceutically acceptable salts or prodrugs thereof show activity as modulators of gluconeogenesis.

AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY

The present invention is a 1,3,8 substituted xanthine derivative of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are as defined in the specification. Compounds of formula (I) and pharmaceutically acceptable salts or prodrugs thereof show activity as modulators of gluconeogenesis.

Quinoxaline derivatives useful in therapy

Compounds of formula (I), wherein A represents N or CH; R1 and R2 independently represent C1-4 alkyl, halo or CF3 ; R3 represents C1-4 alkyl (optionally substituted), C3-7 cycloa